We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma has reached a major milestone in its development in January 2025, with positive topline results from its Phase 3 clinical trial evaluating its microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Enhancing Survival Through Innovative Immune Modulation
We are a late-stage clinical company developing microbiome therapies to modulate the immune system and improve cancer survival.
See News
Corporate profile
Press Releases
July 28, 2025: MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step…
July 7, 2025: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Media Coverage
August 7, 2025: French Tech : Maat Pharma traite les complications de greffe de moelle osseuse – BFM Business (French Only)
July 21, 2025: World’s First Hemato-Oncology Microbiota Therapeutic Among Latest New EU Filings – Citeline
June 25, 2025: Just the Two of Us: Creating Microbiomes to Fight Cancer, ALS, and More – Inside Precision Medicine
June 6, 2025: Eric Soyer, directeur financier Maat Pharma : “demande d’autorisation de mise sur le marché” – Lyon Décideurs (French Only)
Posters
MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe
MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial
